Please use this identifier to cite or link to this item: http://dspace.mediu.edu.my:8181/xmlui/handle/1721.1/3916
Full metadata record
DC FieldValueLanguage
dc.creatorMu, L.-
dc.creatorChan-Park, Mary Bee-Eng-
dc.creatorYue, Chee Yoon-
dc.creatorFeng, S.S.-
dc.date2003-12-15T12:00:00Z-
dc.date2003-12-15T12:00:00Z-
dc.date2004-01-
dc.date.accessioned2013-10-09T02:33:11Z-
dc.date.available2013-10-09T02:33:11Z-
dc.date.issued2013-10-09-
dc.identifierhttp://hdl.handle.net/1721.1/3916-
dc.identifier.urihttp://koha.mediu.edu.my:8181/xmlui/handle/1721-
dc.descriptionA suitable management of the pharmaceutical property is needed and helpful to design a desired nanoparticulate delivery system, which includes the carrier nature, particle size and size distribution, morphology, surfactant stabiliser according to the technique applied, drug-loading ratio and encapsulation efficiency, surface property, etc. All will influence the in vitro release, in vivo behaviour and tissue distribution of administered particulate drug loaded nanoparticles. The main purpose of the present work was to determine the effect of drug loading ratio when employing TPGS as surfactant stabiliser and/or matrix material to improve the nanoparticulate formulation. The model drug employed was paclitaxel.-
dc.descriptionSingapore-MIT Alliance (SMA)-
dc.format532760 bytes-
dc.formatapplication/pdf-
dc.languageen_US-
dc.relationInnovation in Manufacturing Systems and Technology (IMST);-
dc.subjectbiomaterials-
dc.subjectdrug delivery-
dc.subjectsurfactant stabiliser-
dc.subjectPaclitaxel-
dc.subjectD-α -tocopheryl polyethylene glycol 1000 succinate.-
dc.titlePharmaceutical Properties of Nanoparticulate Formulation Composed of TPGS and PLGA for Controlled Delivery of Anticancer Drug-
dc.typeArticle-
Appears in Collections:MIT Items

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.